Document is current
Any future updates will be listed below
-
Authors
Tobi, Allan https://orcid.org/0000-0003-4797-5481
Haugas, Maarja
Rabi, Kristina
Sethi, Jhalak
Põšnograjeva, Kristina
Paiste, Päärn
Jagomäe, Toomas
Pleiko, Karlis
Lingasamy, Prakash
Teesalu, Tambet
-
Funding
Funding for this research was provided by:
Eesti Teadusagentuur (PRG230, PRG1788, EAG79)
EuroNanoMed III (ECM-CART, iNanoGun)
- License Information
-
More Information
Article History
Accepted: 4 July 2024
First Online: 16 July 2024
Declarations
:
: All institutional and national guidelines for the care and use of laboratory animals were followed. Animal experimentation protocols were approved by the Committee of Animal Experimentation of Estonian Ministry of Agriculture (Permit #159). No human subjects or patient data was used in this study.
: Not applicable.
: Tambet Teesalu is an inventor of patents on CendR peptides and shareholder of Lisata Therapeutics, a company that develops iRGD peptide for cancer therapy. Prakash Lingasamy and Tambet Teesalu are patent holders for the PL3 peptide ("Bi-Specific Extracellular Matrix Binding Peptides and Methods of Use Thereof"; WO 2020/161602 A1) []. The rest of the authors declare that they have no competing interests.
